THUNDER BAY, Ontario--(BUSINESS WIRE)--Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, today announced the publication of new research in the Canadian Urological Association Journal (CUAJ) showing that large-scale deletions in mitochondrial DNA (mtDNA) can indicate cellular changes that are associated with the development of cancer. Importantly, these changes and mutations accumulate in a way that enables quantitative measurement and the diagnosis of disease in adjacent, normal tissue or tumor margins through a “field effect” which may occur in advance of the formation of malignant prostate tissue. These insights suggest a paradigm-shifting approach to diagnosing prostate cancer.
